A novel class of lipophilic quinazoline-based folic acid analogues: Cytotoxic agents with a folate-independent locus

British Journal of Cancer

Volumn 79, Issue 11-12, 1999, Pages 1692-1701

  Skelton, L A ^a   Ormerod, M G ^a   Titley, J ^a   Kimbell, R ^a   Brunton, L A ^a   Jackman, A L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CB30865; Cell cycle; Cross resistance; Folate independent; TS; ZM1985833

Indexed keywords

4 [N (7 BROMO 3,4 DIHYDRO 2 METHYL 4 OXO 6 QUINAZOLINYLMETHYL) N (2 PROPYNYL)AMINO] N (3 PYRIDYLMETHYL)BENZAMIDE; ANTINEOPLASTIC AGENT; CB 300179; CB 300189; CYTOTOXIC AGENT; FOLIC ACID DERIVATIVE; FOLINIC ACID; THYMIDINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CLONOGENIC ASSAY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; FLOW CYTOMETRY; FOLATE METABOLISM; GROWTH INHIBITION; ISOTOPE LABELING; LIPOPHILICITY; PRIORITY JOURNAL;

EID: 0032996591     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690270     Document Type: Article

References (33)

1. Bavetsias V, Marriott JH, Melin C, Kimbell R, Boyle FT and Jackman AL (1997) Synthesis and antitumour activity of cyclopenta[g]quinazoline-based antifolates, a novel class of thymidylate synthase (TS) inhibitors. Br J Cancer 75 (Suppl 1): 24
2. Boyd MR (1989) Status of the NCI preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In Cancer: Principles and Practice of Oncology Updates, Vol. 3, De Vita VT, Hellman S and Rosenberg SA (eds). pp. 1-12. Lippincott: Philadelphia
3. Boyd MR, Paull KD and Rubinstein LR (1992) Data display and analysis strategies for the NCI disease-orientated in vitro antitumour drug screen. In Cytotoxic Anticancer Drugs: Models And Concepts for Drug Discovery and Development, Valeriote FA, Corbett T and Baker L (eds), pp. 11-34. Kluwer Academic Publishers: Amsterdam
4. 10-substitutions. In Advances in Tumor Prevention, Detection and Characterisation, Vol. 5, Davis W, Harrap KR and Stathopoulos G (eds), pp. 272-283. Excepta Medica: Amsterdam
5. Charcosset JY (1986) Effects of antineoplastic agents on the cell cycle progression. Biol Cell 58: 135-138
6. Hook KE, Nelson JM, Roberts BJ, Griswold DP and Leopold WR (1986) Cell cycle effects of trimetrexate (CI-898). Cancer Chemother Pharmacol 16: 116-120
7. Jackman AL, Calvert AH, Hart LI and Harrap KR (1984) Inhibition of thymidylate synthetase by the new quinazoline antifolate CB3717; enzyme purification and kinetics. In Purine Metabolism in Man IV, Part B: Biochemical, Immunological and Cancer Research, de Bruyn C, Simmonds H and Miller M (eds), pp. 375-378. Plenum Press: New York
8. 10-propargyl-5,8-dideazafolic acid (CB 3717): development, characterisation, and cross-resistance studies. Cancer Res 46: 2810-2815
9. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res 50: 5212-5218
10. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol 42: 1885-1895
11. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A, Boyle-FT (1995a) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924
12. Jackman AL, Kimbell R, Brown M, Brunton L, Boyle FT (1995b) Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Design 10: 555-572
13. Jackman AL, Kimbell R, Brown M, Brunton L, Harrap KR, Wardleworth JM and Boyle FT (1995c) The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. In Purine and Pyrimidine Metabolism in Man. Advances in Experimemal Medicine and Biology, Vol. 370, Sahota A and Taylor M (eds), pp. 185-B5-188. Plenum Press: New York
14. Jackman AL, Boyle FT and Harrap KR (1996a) Tomudex™ (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 14: 305-316
15. Jackman AL, Skelton LA, Kimbell R, Hughes LR and Boyle FT (1996b) Lipophilic quinazoline analogues of folic acid with 3-pyridylamide replacing the glutamate: evidence for a non-folate locus. Proc Amer Assoc Cancer Res 37: 394
16. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM and Boyle FT (1997a) Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clinical Cancer Res 3: 911-921
17. Jackman AL, Kimbell R, Melin C, Boyle FT, Marriott J and Bavetsias V (1997b) Folate-based (acidic) thymidylate synthase (TS) inhibitors with activity independent of the reduced-folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). Proc Amer Assoc Cancer Res 38: 162
18. Kobayashi H, Takemura Y, Miyachi H, Skelton LA and Jackman AL (1995) Effect of hammerhead ribozyme against thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors. Jpn J Cancer Res 86: 1014-1018
19. 10-propargyl-5,8-dideazafolic acid. Cancer Res 48: 2036-2041
20. Melin C, Kimbell R, Bavetsias V, Marriott JH, Boyle FT and Jackman AL (1997) In vitro activity of the cyclopenta[g]quinazolines, a novel class of thymidylate synthase (TS) inhibitors. Br J Cancer 75 (Suppl 1): 24
21. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumour cell lines. J Natl Cancer Inst 11: 757-776
22. 10-propargyl-5,8-dideazafolic acid (ICI 198583); a novel folate-based TS inhibitor. Cancer Res 52: 1137-1143
23. Ormerod MG (1994) Analysis of DNA-general methods. In Flow Cytometry: A Practical Approach, 2nd Edn, Ormerod MG (ed). pp. 118-135. Oxford University Press: New York
24. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumour cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092
25. Skelton LA, Kimbell R, Brunton L, Boyle FT and Jackman AL (1994a) Lipophilic inhibitors of thymidylate synthase: 2-pyridyl quinazolines. Br J Cancer 69 (Suppl XXI): 41
26. Skelton LA, Kimbell R, Brunton LA, Boyle FT and Jackman AL (1994b) 2-Pyridyl quinazolines as inhibitors of thymidylate synthase. Proc Amer Assoc Cancer Res 35: 301
27. Skelton LA, Kimbell R, Boyle FT, Jackman AL (1997) Aminomethyl pyridine analogues of the quinazoline antifolate ICI 198583 with a folate-independent locus of action. In Chemistry and Biology of Pteridines and Folates, Pfleiderer W and Rokos H (eds), pp. 209-212. Blackwell Science: Berlin
28. Skelton LA, Ormerod MG, Titley J and Jackman AL (1998) Cell cycle effects of CB30865 - A lipophilic quinazoline-based analogue of the antifolate TS inhibitor, ICI 198583, with an undefined mechanism of action. Cytometry 33: 56-66
29. Stephens TC, Smith MN, Waterman SE, McCloskey ML, Jackman AL and Boyle FT (1993) Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors. In Chemistry and Biology of Pteridines and Folates, Ayling J, Nair MG and Baugh CM (eds), pp. 589-582. Plenum Press: New York
30. Taylor GA, Jackman AL, Balmanno K, Hughes LR and Calvert AH (1989) Estimation of the in vitro and in vivo inhibitory effect of antifolates upon thymidylate synthase (TS) in whole cells. In Purine and Pyrimidine Metabolism in Man VI. Part B, Mikanagi K, Nishioka K and Kelley WN (eds), pp. 383-388. Plenum: New York
31. Taylor IW and Tattersall MNH (1981) Methotrexate cytotoxicity in cultured human leukaemic cells studied by flow cytometry. Cancer Res 51: 1549-1558
32. Twentyman PR and Luscombe M (1987) A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285
33. Ward WHJ, Kimbell R and Jackman AL (1992) Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 43: 2029-2031